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The study of the reactivity of the pyrazole derivative 1-[MeO-(CH2)2]-3,5-Ph2-4-(CH2Fc)–(C3N2) (1, 38 
Fc = ferrocenyl) with Na2[PdCl4], Pd(OAc)2, and [MCl2(dmso)2] (M = Pd or Pt, dmso = dimethyl 39 
sulfoxide) has allowed us to isolate trans-[Pd{κ-N-(1-{MeO(CH2)2}-3,5-Ph2-4-{CH2Fc}–40 
{C3N2})}2Cl2] (2), [Pd{κ2-C,N(1-{MeO(CH2)2}-3-{C6H4}-5-Ph-{C3N2})}{κ-N-(1-{MeO(CH2)2}-41 
3,5-Ph2-4-{CH2Fc}–{C3N2})}Cl] (3), [Pd{κ2-C,N(1-{MeO(CH2)2}-3-{C6H4}-4-{CH2Fc}-5-Ph-42 
{C3N2})}Cl-(PPh3)] (4), and the trans (5) and cis (6) isomers of [Pt{κ-N-(1-{MeO(CH2)2}-3,5-Ph2-4-43 
{CH2Fc}–{C3N2})}Cl2(dmso)]. Compound 1 acts as a N (in 2, 5, and 6) or (C,N)– donor ligand (in 4) 44 
and shows both binding modes in 3. The cytotoxic assessment of 1–6 against MCF7, MDA-MB231 45 
(breast), and HCT-116 (colon) cancer cell lines reveal that (1) 1 is more potent than 1-[MeO(CH2)2]-46 
3,5-Ph2-(C3HN2) (V), (2) 2–6 have cytotoxic activity, (3) 2 and 3 are less active than 4–6, and (4) 6 is 47 




Pyrazole derivatives are valuable cores for the design and synthesis of compounds with interesting 52 
applications in different fields, such as catalysis, agrochemistry, supra- and macromolecular chemistry, 53 
as well as biomedicine.[1] Compounds of this type with outstanding anticancer, antiviral, antimicrobial, 54 
antiglycemic, or even antiallergenic activities have been described.[2–5] Moreover, pyrazoles are useful 55 
ligands in coordination and organometallic chemistry.[6] The nature and position of the substituents on 56 
the ring, the metal ion (its oxidation number and environment), and even the ancillary ligands (donor 57 
atoms, electron-donor ability, bulk, and relative orientation in the complex) modify the properties and 58 
activities of the complexes.[7] Among the wide variety of transition metal complexes derived from 59 
pyrazole, those containing PdII or PtII ions are probably the most attractive mainly owing to their 60 
potential biological activity.[8,9] Compounds of this kind with greater antitumor activity and lower 61 
toxicity than cis-[PtCl2(NH3)2] (cisplatin) or antibacterial activity have been reported.[8,9] 62 
On the other hand, bioorganometallic chemistry is a fast developing area of increasing interest, and the 63 
idea of using organometallic complexes in drug discovery is becoming more and more popular.[10–12] 64 
Antimalarials, antibacterials, and neuroprotectors based on organometallic compounds have been 65 
described.[10,11] In this context, ferrocene derivatives are probably among those with the best 66 
prospects.[13–15] One of the most promising strategies used to achieve new therapeutic agents consists 67 
of the incorporation of a ferrocenyl (Fc) unit on the scaffold of a biologically active molecule.[10–15] 68 
Commonly, this change increases the biological activity of the molecule and widens its range of 69 
application. Owing to the increasing interest in pyrazole derivatives and new ferrocene-based drugs or 70 
prodrugs, several groups have centered their attention on the design and synthesis of mixed ferrocenyl–71 
pyrazole derivatives.[16] Unfortunately, studies on their coordination ability to PdII or Previous studies 72 
on the cytotoxic activities of pyrazoles 1-R1-3,5-(R2)2–(C3HN2) (types IV and V in Figure 1) and their 73 
PdII or PtII complexes against MCF7 and MDAMB231 breast cancer cell lines have shown that 74 
compounds with R2 = H or Me are less active than those with R2 = Ph.[9b] Moreover, the replacement 75 
of the Me2N(CH2)2 [9b] group by a MeO(CH2)2 unit increases their cytotoxic activity.[ 9a] In view of 76 
these findings and the increasing interest in new ferrocene derivatives with bioactive moieties, now we 77 
present the hybrid Fc/pyrazole 1-[MeO(CH2)2]-3,5-Ph2-4-(CH2Fc)–(C3N2) (1, Figure 1) and report its 78 
utility as a ligand for the synthesis of heterodi- or heterotrimetallic complexes containing FeII and PtII 79 
or PdII ions and a study of the antitumoral activity of the compounds against breast (MDA-MB231 and 80 
MCF7) and colon (HCT-116) cancer cell lines. 81 
82 
RESULTS AND DISCUSSION 83 
 84 
Synthesis and Characterization of Ligand 1 Ligand 1 was prepared in good yield (80%) by the alkylation 85 
of 3,5-Ph2-4-(CH2Fc)–(C3HN2) (IIa)[18] with 2-chloroethyl methyl ether (Scheme 1) by using the 86 
same procedure as that described for indigo[19] or the N-methylated derivative 1-Me-3,5-Ph2-4-87 
(CH2Fc)–(C3N2).[18] 88 
Compound 1 is a stable yellow solid at 298 K and exhibits high solubility in CH2Cl2, CHCl3, and 89 
acetone. The characterization data (Supporting Information) agreed with the proposed formula, and 90 
NMR spectroscopy studies confirmed the presence of the MeO(CH2)2 unit attached to the nitrogen 91 
atom of the pyrazole ring. 92 
 93 
Palladium(II) Complexes 94 
In a first attempt to evaluate the potential coordination abilities of 1 to PdII ions, its reactivity with 95 
Na2[PdCl4], [PdCl2(dmso)2] (dmso = dimethyl sulfoxide), and Pd(OAc)2 was studied under different 96 
experimental conditions (Table 1, Entries 1–3; Scheme 2). 97 
The treatment of 1 with Na2[PdCl4] (molar ratios 1:1 or 1:2) in MeOH at 298 K gave a yellow solid 98 
(Table 1, Entry 1; Scheme 2, Step A). Its characterization data (Supporting Information) agreed with 99 
those expected for the heterotrimetallic product 2, and its crystal structure confirmed the presence of 100 
[Pd{κ-N-(1-{MeO(CH2)2}-3,5-Ph2-4-{CH2Fc}–{C3N2})}2Cl2] (Figure 2). 101 
The PdII ion is located on an inversion center and, consequently, the relative disposition of the two 102 
identical ligands is trans. The Pd–Cl bond length [2.3013(17) Å] is similar to those reported for most 103 
trans-[Pd(κ-N-1-R1-3,5-Ph2–pyrazole) 2Cl2] complexes[9a,20,21] and its analogue Va [Figure 1; Pd1–104 
Cl1 2.3044(5) Å].[9a] The Pd–N1 bond length [2.007(4) Å] is slightly shorter than that in Va [Pd1–N1 105 
2.020(19) Å] but only by an insignificant amount.[9a] The Pd1···H5 separation of 2.9 Å suggests a 106 
weak agostic interaction.[22] The pyrazolyl rings are planar and nearly orthogonal to the “PdCl2” unit. 107 
The phenyl rings form angles of 53.3 and 58.9° with the heterocycle. In the crystal, the molecules are 108 
assembled through C–H···π intermolecular contacts[23] involving the H24 atom and the C5H5 ring (the 109 
separation between H24 and the centroid of the C1–C5 ring is 2.604 Å). 110 
Compound 2 was also isolated from the reaction of ligand 1 and [PdCl2(dmso)2] (in molar ratios of 1:1 111 
or 2:1) in MeOH under reflux (Table 1, Entry 2; Scheme 2, Step A). It should be noted that no evidence 112 
of the formation of PdII complexes with a Pd–OMe bond or arising from the cyclometalation of any of 113 
the rings was detected when Na2[PdCl4] or [PdCl2(dmso)2] was used (Table 1, Entries 1 and 2). 114 
As (1) cyclopalladated complexes are attracting great interest in a wide variety of areas,[24,25] 115 
especially in view of their potential biological activity as cytotoxic, antimalarial, and antioxidants 116 
agents,[25a,26,27] and (2) Pd(OAc)2 is a more potent metallating agent than Na2[PdCl4] or 117 
[PdCl2(dmso)2],[17,26,29] we also studied the reactivity of 1 with Pd(OAc)2. When equimolar amounts 118 
of Pd(OAc)2 and 1 were heated to reflux in toluene for 24 h, the formation of Pd0 was detected on the 119 
walls of the flask. Subsequent filtration though a Celite pad followed by column chromatography gave a 120 
brownish solid (3; Table 1, Entry 3; Scheme 2, Step B). 121 
The IR spectrum of 3 exhibited the typical bands for a monodentate OAc– ligand.[28] The 1H NMR 122 
spectrum of 3 showed two sets of superimposed signals with relative intensities 1:1 and, thus, suggested 123 
the presence of two different and inequivalent units of ligand 1. Moreover, in one of the sets of 124 
resonances, the signals for 3a-H and 4a-H of the phenyl ring at the 3-position of the pyrazole ring 125 
appeared high-field shifted in relation to the signals of the free ligand and to those of 2. This trend, also 126 
observed for the cyclopalladated compounds derived from V,[9a] is typical of palladacycles containing 127 
bidentate [C(sp2, phenyl), N]– ligands.[30,31] These findings suggested one of the units of 1 adopted 128 
this binding mode in 3, whereas the other acted as a N donor. 129 
To confirm this hypothesis, further reactivity studies were performed. The treatment of 3 with LiCl first 130 
and then an equimolar amount of PPh3 gave a deep brown solid after concentration of the reaction 131 
solution (Table 1, Entry 4; Scheme 2, Step C). The TLC and 1H NMR spectrum of the raw material 132 
revealed the presence of the free ligand (1) and a new PdII complex (4). The two products (1 and 4) 133 
were separated in a molar ratio of ca. 1:1 by SiO2 column chromatography. The elemental analysis and 134 
mass spectrum of 4 (Supporting Information) agreed with those expected for [Pd{κ2-C,N-(1-135 
{MeO(CH2)2}-3-{C6H4}-4-{CH2Fc}-5-Ph-{C3N2})}Cl(PPh3)] (Scheme 2, Step C), in which the 136 
PPh3 ligand is in a cis arrangement to the metallated carbon atom.[32] The position of the singlet in the 137 
31P{1H} NMR spectrum of 4 (δ = 43.6 ppm) is very similar to that of [Pd{κ2-C,N-(1-{MeO(CH2)2}-3-138 
{C6H4}-5-Ph-{C3HN2})}-Cl(PPh3)][9a] and falls in the range reported for other palladacycles with 139 
“Pd{C(sp2 phenyl),N}Cl(PPh3)” cores.[17,18,26,29] 140 
 141 
Platinum(II) Complexes 142 
To compare the effect produced by the binding of the MII atom to ligand 1, we also studied the 143 
reactivity of 1 with cis-[PtCl2(dmso)2][33] under different experimental conditions (Table 1, Entries 5 144 
and 6). The treatment of these two reagents (in molar ratios 1/PtII = 1 or 2) in MeOH under reflux for 1 145 
h followed by the partial evaporation of the solvent gave a yellow solid (Table 1, Entry 5; Scheme 2, 146 
Step D), which was identified as trans-[Pt{κ-N-(1-{MeO(CH2)2}-3,5-Ph2-4-{CH2Fc}–147 
{C3N2})}Cl2(dmso)] (5). These results are different from those obtained with [PdCl2(dmso)2] (Table 1, 148 
Entry 2), which gave the heterotrimetallic complex 2. 149 
In view of the increasing interest in the cytotoxic activities of the trans and cis isomers of PtII 150 
complexes containing mono-  (L) or bidentate (L,L ) N-donor ligands,[34,35] we also attempted the 151 
preparation of the cis isomer of 5. Several strategies were used to achieve this aim. In a first attempt, the 152 
reaction period (t) was increased gradually from 1 to 72 h. Under these experimental conditions, two 153 
products were isolated by SiO2 column chromatography. The major component was the trans isomer 154 
(5); the characterization data of the minor product (6) agreed with those expected for cis-[Pt{κ-N-(1-155 
{MeO(CH2)2}-3,5-Ph2-4-{CH2Fc}–{C3N2})}Cl2(dmso)] (Scheme 1, Step E), and its crystal structure 156 
(see below) confirmed this result. These two isomers were isolated in a 5/6 molar ratio of 1.0:0.65, but 157 
larger reaction periods did not produce significant variations in their relative abundance (for t = 72 h, the 158 
5/6 molar ratio was 1.0:0.70). 159 
When the reaction was performed in the presence of NaOAc (molar ratio OAc–/PtII = 2) and in a 160 
toluene/MeOH mixture (5:1) under reflux for 24 h, the 5/6 molar ratio decreased (Table 1, Entry 6), and 161 
the cis isomer (6) became the major product. 162 
Isomers 5 and 6 were separated by SiO2 column chromatography and characterized by elemental 163 
analysis, mass spectrometry, IR spectroscopy, and NMR spectroscopy (Supporting Information). Their 164 
1H NMR spectra showed (1) one (for 5) or two singlets (for 6) of identical intensity for the protons of 165 
the dmso ligand and (2) two well-resolved triplets (for 5) or four multiplets (for 6) for the –(CH2)2– 166 
protons of the pendant arm. The 195Pt{1H} NMR spectra showed a singlet in both cases, and the 167 
chemical shifts were consistent with those of PtII compounds with a “N,Cl2,S(dmso)” set of donor 168 
atoms. The magnitude of the shift [Δδ = δ(6) – δ(5) = 123 ppm] is similar to those reported for related 169 
cis and trans isomers of PtII compounds with “Pt(N-donor ligand)Cl2(dmso)” cores.[17,27a,36] 170 
The slow evaporation of a CH2Cl2 solution of 6 layered with MeOH at 298 K produced crystals suitable 171 
for X-ray diffraction. The crystal structure confirmed the existence of [Pt{κ-N-(1-{MeO(CH2)2}-3,5-172 
Ph2-4-{CH2Fc}–{C3N2})}Cl2-(dmso)] (6), CH2Cl2, and MeOH molecules in a 1:1:1 ratio. In the 173 
heterodimetallic molecules of 6 (Figure 3), the PtII atom is bound to nitrogen atom N1 of the pyrazolyl 174 
unit, the sulfur atom S1 of the dmso ligand, and two Cl– ligands (Cl1 and Cl2) in a cis arrangement 175 
[Cl1–Pt–Cl2 bond angle: 89.86(5)°]. The bond lengths and angles around the PtII center are similar to 176 
those of cis-[Pt{κ-N-1-(CH2Fc)-3,5-Ph2–(C3HN2)}Cl2(dmso)], which contains pyrazole I as a N-donor 177 
ligand.[17a] 178 
The three rings of the “3,5-Ph2-C3N2” backbone are planar. The main plane of the heterocycle forms an 179 
angle of ca. 74.01° with the coordination plane of the PtII ion, and the phenyl rings (C15–C20 and C21–180 
C26) are not coplanar with the pyrazole ring (the angles between the main planes are 66.9 and 63.6°). 181 
The orientation of these two phenyl rings allows intramolecular C–H···π interactions between (1) the 182 
C9–H9 bond of the C5H4 ring and the C21–C26 phenyl ring and (2) the other phenyl ring and the 183 
hydrogen atom (H30) of the dmso ligand. 184 
In the crystal, the separation between the centroids of the cyclopentadienyl (Cp) ring of a molecule at (x, 185 
y, z) and the C5H4 ring of a proximal unit is 3.295 Å, which indicate the existence of π–π stacking. 186 
Moreover, two of the hydrogen atoms of the OMe unit (H29A and H29B) are involved in intermolecular 187 
C–H···π interactions with the substituted ring of the Fc group and the pyrazolyl unit, respectively, of 188 
another molecule at (1/2 – x, 1/2 – y, 1 – z). 189 
 190 
Study of Cytotoxic Activities 191 
In a first stage, two human breast cancer cell lines (MCF7 and MDA-MB231) were used to test the 192 
cytotoxic activity of ligand 1 and complexes 2–6. Cisplatin (as a positive control) was also evaluated 193 
under the same experimental conditions. A summary of the results obtained for the inhibition 194 
concentrations (IC50 in μm) of ligand 1, pyrazoles IV and V (Figure 1), and complexes 2–6 is presented 195 
in Table 2. For comparison, the data for related PdII complexes derived from V are also included. 196 
Ligand 1 exhibited outstanding activity (IC5  0 5.8 μm, greater than that of cisplatin) against these two 197 
breast cancer cell lines. A comparison of the data presented in Table 2 for 1 and IV allows us to 198 
conclude that the replacement of the hydrogen atom at the 4-position of the pyrazole ring (in IV) by the 199 
–CH2Fc unit to give 1 enhances the cytotoxic activity against these two (MCF7 and MDA-MB231) cell 200 
lines. Moreover, as shown in Figure 4, the framework and substitution pattern of the pyrazole has a great 201 
influence on its cytotoxic activity. For the studied pyrazoles 1, IV, and V, the cytotoxicity increases in 202 
   the order V IV cisplatin   1 (against MCF7 and MDA-MB231 cell lines) 203 
To evaluate the effect produced by the binding of the PdII or PtII atoms to the ligand, we also 204 
investigated the cytotoxic activity of the new complexes against these cancer cell lines. The new PdII 205 
complexes 2–4 exhibit cytotoxic activity (Figure 5 and Table 2) but are less active than the free ligand 1. 206 
However, in general, they are more potent than their analogues derived from V. This suggests once more 207 
that the –CH2Fc group at the 4-position of the pyrazole ring increases their activity. 208 
Better results were obtained for the trans (5) and cis (6) isomers of: [Pt{κ-N-(1-{MeO(CH2)2}-3,5-Ph2-209 
4-{CH2Fc}–{C3N2})}Cl2(dmso)]. These compounds exhibited outstanding  activity (IC50 8.3 μm) 210 
against the MCF7 and in the MDA-MB231 breast cancer cell lines. The cytotoxic activities increase 211 
according to sequences: 212 
3<2<4<cisplatin<5<6 (for MCF7 cell line) 213 
3<2<4<5<cisplatin<6 (for MDA-MB231 cell line) 214 
These trends are practically identical except for the position of cisplatin and reveal that the 215 
heterotrimetallic compounds 2 and 3 are less potent than the heterodimetallic derivatives 4–6. 216 
In view of the outstanding results obtained for some of the new products against the two breast cancer 217 
cell lines, we decided to study their effect on the cisplatin-resistant HCT-116 colon cell line. A 218 
comparison of the data (Table 2 and Figure 5) shows that their cytotoxic activity against this cell line 219 
increases as follows:  220 
3≤4<2<5<cisplatin<1<6 221 
Among the new products prepared in this work, complex 6 and the free ligand 1 are the most active 222 
ones. Their potency against the HCT-116 cell line is greater (10 and 14 times, respectively) than that of 223 




The new hybrid ferrocenyl–pyrazole derivative 1-[MeO-(CH2)2]-3,5-Ph2-4-(CH2Fc)–(C3N2) (1) has 228 
been prepared. The study of its reactivity with different PdII and PtII salts and complexes allowed us to 229 
isolate and characterize three PdII compounds 2–4 and the trans (5) and cis (6) isomers of [Pt{κ-N-(1-230 
{MeO(CH2)2}-3,5-Ph2-4-{CH2Fc}–{C3N2})}Cl2(dmso)]. We have also proved that 1 is a versatile 231 
and valuable ligand. It may (1) adopt two different binding modes {N donor (in 2, 5, and 6), [C(sp2, 232 
phenyl), N]– (in 3), or even both simultaneously in the same complex (4)} and (2) produce heterotri- (2 233 
and 3) or heterodimetallic complexes 4–6. 234 
The new products 1–6 exhibit growth inhibitory activity against breast (MDA-MB231 and MCF7) and 235 
colon (HCT- 116) human cancer cell lines. We have also demonstrated that the presence of the CH2Fc 236 
moiety at the 4-position of the pyrazole ring plays a key role in determining the activity of the products. 237 
Against the three cell lines, the PdII complexes 2 and 3 are less potent than the PtII derivatives 5 and 6 238 
and the free ligand 1. Complex 6 is clearly more active than its trans isomer (5) against the three cell 239 
lines assayed. 240 
The free ligand and the cis isomer of [Pt{κ-N-(1-{MeO(CH2)2}-3,5-Ph2-{C3N2}-4-{CH2Fc}–241 
{C3N2})}Cl2-(dmso)] (6) are the most potent against the three cell lines. Their activities against the 242 
cisplatin-resistant colon cell line (HCT-116) are especially relevant [ca. 10 (for 1) and 14 (for 6) times 243 
bigger than that of cisplatin]. 244 
Although 6 has a slightly greater inhibitory effect than 1 against the cell lines MDA-MB231 and 245 
HCT116, the new ligand is particularly attractive because it does not contain PtII and consequently 246 
might not produce the typical and undesirable side effects of conventional PtII-based drugs. Thus, 247 
among the new products presented here, compounds 1 and 6 appear to be excellent candidates for 248 
further studies mainly centered on (1) the study of their cytotoxic activities against other cancer cell 249 
lines (i.e., lung, ovarian, etc.), (2) the investigation of their effect on normal nontumor cells (i.e., 250 
fibroblasts), (3) additional studies (cell cycle arrest, induction of apoptosis, etc.) to gain further insights 251 
into their mechanism of action, and (4) additional studies on their potential utility in combined therapies. 252 
Preliminary studies in these fields are underway. 253 
254 
EXPERIMENTAL SECTION 255 
 256 
Materials and Methods: 3,5-Ph2-4-(CH2Fc)–(C3HN2), Na2[PdCl4], and complexes [MCl2(dmso)2] 257 
(M = Pd or Pt) were prepared as described previously,[17,31,36–38] and the remaining reagents were 258 
obtained from commercial sources and used as received. The success of the synthesis of the PtII 259 
complexes (5 and 6) is strongly dependent on the quality of the methanol; the presence of water results 260 
in the formation of metallic platinum, other undesirable minor byproducts, and a significant decrease in 261 
the yield. Thus, the use of high quality MeOH (HPLC grade) is required. The remaining solvents used 262 
were dried and distilled before use.[39] Elemental analyses were performed at the Serveis de Cientifico-263 
Tècnics (Universitat de Barcelona). Mass spectrometry (ESI+) was performed at the Servei 264 
d’Espectrometria de Masses (Universitat de Barcelona). The infrared spectra in the range ν˜ = 4000–400 265 
cm–1 were obtained with a Nicolet 400 FTIR instrument with samples as KBr pellets, and far-IR spectra 266 
were recorded with a Bomen-DA3 instrument by using polyethylene discs. Thin layer chromatography 267 
(TLC) was performed with SiO2 plates (Merck silica gel 60 F254). The UV/Vis spectra of solutions of 268 
the compounds in CH2Cl2 were recorded at 298 K with a Cary 100 scan Varian UV spectrometer. The 269 
routine 1H NMR spectra were recorded with a Mercury 400 MHz instrument at the Indian Institute of 270 
Chemical Biology of Kolkata and at the Serveis Cientifico-Tècnics (Universitat de Barcelona). The 271 
high-resolution 1H NMR spectra of the compounds dissolved in CDCl3 (99.9%) containing SiMe4 as an 272 
internal reference were obtained with a Varian VRX-500 instrument or a Bruker Avance DMX 500 273 
MHz instrument at 298 K. The 31P{1H} (of 4) and 195Pt{1H} NMR spectra (of CDCl3 solutions of 5 274 
and 6) were recorded with a Varian 300 MHz instrument with P(OMe)3 [δ(31P) = 140.17 ppm] and 275 
H2[PtCl6] [δ(195Pt) = 0.0 ppm], respectively, as references. The coupling constants (J) are given in Hz, 276 
and chemical shifts (δ) are given in ppm. 277 
1-[MeO(CH2)2]-3,5-Ph2-4-(CH2Fc)–(C3N2) (1): To a solution con taining 3,5-Ph2-4-(CH2Fc)–278 
(C3HN2) (IIa, 1.0 g, 2.39  10–3 mol)[17a] and toluene (30 mL), benzyltriethylammonium chloride 279 
(BTAC; 136 mg, 6.0  10–4 mol) and an aqueous NaOH (40%) solution (7 mL) were added. Then, a 280 
threefold excess of ClCH2CH2OMe (0.66 mL, 7.2  10–3 mol) was added dropwise to the mixture with 281 
stirring. Once this process had finished, the resulting mixture was kept at 370 K for 24 h. After this 282 
period, H2O (50 mL) was added, and then the mixture was extracted with toluene (2  25 mL). The 283 
organic layers were combined, dried with Na2SO4, and then filtered. The resulting filtrate was 284 
concentrated to dryness with a rotary evaporator. The residue was then dissolved in the minimum 285 
amount of CH2Cl2 (5 mL) and passed through a short SiO2 column (5.0 cm  2.0 cm). Elution with 286 
CH2Cl2 produced a deep yellow band, which was collected and concentrated to dryness with a rotary 287 
evaporator to give 1. The solid formed was then dried in vacuo for 2 d (yield: 911 mg, 80%). 288 
trans-[Pd{κ-N-(1-{MeO(CH2)2}-3,5-Ph2-4-{CH2Fc}–{C3N2})}2Cl2] (2): This product can be 289 
obtained with Na2[PdCl4] or cis-[PdCl2- (dmso)2] (methods a and b, respectively). 290 
Method a: Ligand 1 (146 mg, 3.1  10–4 mol) was introduced to an Erlenmeyer flask, and then a 291 
solution containing Na2[PdCl4] (45 mg, 1.5  10–4 mol) and MeOH (5 mL) was added. The resulting 292 
mixture was protected from the light with aluminium foil and stirred at 298 K for 1 h. The yellow solid 293 
formed was collected, washed with methanol (2  2 mL portions), air-dried, and then dried in vacuo for 3 294 
d (yield: 121 g, 70 %). 295 
Method b: [PdCl2(dmso)2] (50 mg, 1.5  10–4 mol) was suspended in methanol (30 mL), and the 296 
suspension was heated under reflux until the solid dissolved completely. Then, the hot solution was 297 
filtered, and the filtrate was poured into an Erlenmeyer flask containing ligand 1 (143 mg, 3.0  10–4 298 
mol). The container was protected from the light with aluminium foil, and the reaction mixture was 299 
heated under reflux for 2 h. The solid formed was collected, washed (as in method a), air-dried, and then 300 
dried in vacuo for 2 d (yield: 137 mg, 80 %). 301 
[Pd{κ2-C,N-(1-{MeO(CH2)2}-3-{C6H4}-4-{CH2Fc}-5-Ph–{C3N2})}-(κ-N-1-{MeO(CH2)2}-3,5-302 
Ph2-4-{CH2Fc}–{C3N2})(OAc)] (3): A mixture of 1 (238 mg, 5    10–3 mol) , Pd(OAc)2 (113 mg, 303 
5  10–3 mol), and toluene (20 mL) was protected from the light with aluminium foil and heated under 304 
reflux for 24 h. After this period, the hot mixture was carefully filtered through a Celite pad, and the 305 
filtrate was cooled and kept aside. The Celite was then washed with small portions of CHCl3 until 306 
colorless mother liquors were obtained. These washings were combined with the filtrate and 307 
concentrated to dryness with a rotary evaporator. The residue was then treated with the minimum 308 
amount of CHCl3 (ca. 5 mL) and passed through a SiO2 chromatographic column (120 mm  18 mm). 309 
Elution with CHCl3 produced a wide yellow band that gave small amounts of 1 (ca. 15 mg) after 310 
concentration. Once this band was collected, a CHCl3/MeOH mixture (100:1) produced the release of a 311 
brownish band, which gave 3 after concentration by rotary evaporation. The solid formed was first air-312 
dried and dried in vacuo for 3 d (yield: 208 mg, 74%). 313 
[Pd{κ2-C,N-(1-{MeO(CH2)2}-3-{C6H4}-4-{CH2Fc}-5-Ph–{C3N2})}Cl(PPh3)] (4): Compound 3 314 
(115 mg, 1  10–4 mol) was dissolved in acetone (5 mL). Then, an excess of LiCl (6.5 mg, 1.5  10–4 315 
mol) was added. The reaction mixture was protected from the light, stirred at 298 K for 1 h, and then 316 
filtered. The filtrate was concentrated to dryness with a rotary evaporator, the residue was stored in a 317 
SiO2 desiccator overnight. The residue was then dissolved in the minimum amount of CH2Cl2 (ca. 15 318 
mL) and treated with PPh3 (27 mg, 1.0  10–4 mol); the mixture was stirred at 298 K for 1 h and then 319 
filtered. The deep yellow solution was concentrated to ca. 5 mL with a rotary evaporator. After cooling 320 
to room temperature, the solution was purified by SiO2 column chromatography (3.0  1.2 cm2). Elution 321 
with CH2Cl2 produced a pale yellow band, which gave the free ligand 1 (41 mg) after concentration to 322 
dryness. Once this band was collected, a CH2Cl2/MeOH mixture (100:0.5) was used as the eluent. This 323 
produced an additional band, which was collected and concentrated with a rotary evaporator to give 4 as 324 
a brownish solid. This product was collected, air-dried, and finally dried in vacuo for 2 d (yield: 79 mg, 325 
90 %). trans-[Pt{κ-N-(1-{MeO(CH2)2}-3,5-Ph2-4-{CH2Fc}–{C3N2})}-Cl2(dmso)] (5): cis-326 
[PtCl2(dmso)2] (225 mg, 5.3  10–4 mol) was treated with methanol (20 mL). The resulting suspension 327 
was protected from the light with aluminium foil, and the suspension was heated under reflux until the 328 
solid dissolved completely. Then, the hot solution was carefully filtered, and the filtrate was poured into 329 
an Erlenmeyer flask containing ligand 1 (269 mg, 5.3  10–4 mol). The resulting mixture was heated 330 
under reflux for 1 h. After this period, the bright yellow solution was concentrated with a rotary 331 
evaporator until a solid was obtained. The flask was cooled to ca. 298 K, and the solid that formed was 332 
collected by filtration and dried in vacuo for 2 d (yield: 0.233 mg, 76%). 333 
cis-[Pt{κ-N-(1{MeO(CH2)2}-3,5-Ph2-4-{CH2Fc}–{C3N2})}-Cl2(dmso)] (6)·CH2Cl2·MeOH: 334 
Ligand 1 (254 mg, 5.3  10–4 mol) and cis-[PtCl2(dmso)2] (225 mg, 5.3  10–4 mol) were dissolved in 335 
toluene (20 mL). Then, a solution containing an equimolar amount of NaOAc (87 mg, 1.06  10–3) 336 
dissolved in MeOH (5 mL) was added dropwise with stirring at 298 K. The reaction mixture was heated 337 
under reflux for 24 h. After this period, the deep orange solution that formed was filtered, and the filtrate 338 
was concentrated to dryness with a rotary evaporator and kept in a desiccator overnight. The residue was 339 
then dissolved in the minimum amount of CH2Cl2. The undissolved products were removed by 340 
filtration, and the filtrate was passed through a short SiO2 column (4.0 cm  1.0 cm). Elution with 341 
CH2Cl2 produced a yellowish band, which gave the trans isomer 5 (67 mg) after concentration. Next, a 342 
mixture of CH2Cl2/MeOH (100:1) was used, and the orange band was concentrated to dryness by rotary 343 
evaporation. The solid formed, 6, was collected, air-dried for 24 h, and then dried in vacuo for 2 d (259 344 
mg). Crystals of 6·CH2Cl2·MeOH were obtained at 298 K by the slow evaporation of a saturated 345 
solution of 6 in CH2Cl2 layered with an identical volume of MeOH.  346 
Crystallography: Prismlike crystals of 2 and 6·CH2Cl2·MeOH (sizes in Table 3) were used for the X-347 
ray crystallographic analysis. The X-ray intensity data were measured with a D8 Venture system 348 
equipped with a multilayer monochromator and a Mo high-brilliance Microfocus Source (λ = 0.71073 349 
Å). The frames were integrated with the Bruker SAINT software package by using a narrow-frame 350 
algorithm. The final cell constants (Table 3) are based upon the refinement of the XYZ centroids of 351 
3561 reflections above    2σ(I) with 5.11 2θ 50.26°. The data were corrected for absorption effects by 352 
the multiscan method (SADABS). The ratio of minimum to maximum apparent transmission was 0.779. 353 
For 2, the integration of the data with a monoclinic unit cell yielded a total of 10506 reflections to a 354 
maximum θ angle of 25.13° (0.84 Å resolution), of which 4519 were independent (average redundancy 355 
2.325, completeness: 98.8%, Rint = 4.42%) and 3146 (69.62%) were greater than 2σ(F2). For 356 
6·CH2Cl2·MeOH, the integration of the data with a monoclinic unit cell yielded a total of 28067 357 
reflections to a maximum θ angle of 25.11° (0.84 Å resolution), of which 6261 were independent 358 
(average redundancy 4.483, completeness: 99.4%, Rint = 8.20%, Rsig = 4.65%) and 5497 (87.80%) 359 
were greater than 2σ(F2). 360 
These structures were solved and refined with the Bruker SHELXTL software package[40] in the space 361 
groups P21/c (for 2) and C2/c (for 6·CH2Cl2·MeOH). The final anisotropic full-matrix least-squares 362 
refinement on F2 with 302 (for 2) or 413 (for 6·CH2Cl2·MeOH) variables converged at R1 = 6.58 (for 363 
the observed data and wR2 = 17.62% for all data) and 3.94% (for the observed data and wR2 = 10.92% 364 
for all data), respectively. The goodness-of-fit values were 1.044 (for 2) and 1.028 (for 365 
6·CH2Cl2·MeOH). 366 
For 2, the largest peak in the final difference electron density synthesis was 2.237 e/Å3 and the largest 367 
hole was –1.473 e/Å3 with a root mean square (RMS) deviation of 0.128 e/Å3. On the basis of the final 368 
model, the calculated density was 1.465 g/cm3, and F(000) was 1160 e. For 6·CH2Cl2·2MeOH, the 369 
largest peak in the final difference electron density synthesis was 2.521 e/Å3, and the largest hole was –370 
2.829 e/Å3 with an RMS deviation of 0.182 e/Å3. On the basis of the final model, the calculated density 371 
was 1.792 g/cm3, and F(000) was 3760 e–. 372 
CCDC-1014331 (for 2) and -1014332 (for 6·CH2Cl2·MeOH) contain the supplementary 373 
crystallographic data for this paper. These data can be obtained free of charge from The Cambridge 374 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. Cell Cultures: Breast cancer 375 
(MCF7 and MDA-MB231) cells (from European Collection of Cell Cultures, ECACC) and colon 376 
adenocarcinoma (HCT116) cells (from the American Type Culture Collection) were used in all of the 377 
experiments. The cells were grown as monolayer cultures in minimum essential medium (DMEM with 378 
l-glutamine, without glucose and without sodium pyruvate) in the presence of 10% heat-inactivated fetal 379 
calf serum, 10 mm d-glucose, and 0.1% streptomycin/penicillin under standard culture conditions.  380 
Cell Viability Assays: For these studies, the compounds were dissolved in 100% DMSO at 50 mm as 381 
stock solutions; then, serial dilutions were performed with DMSO (1:1; in this way, the DMSO 382 
concentrations in the cell media were always the same); finally, 1:500 dilutions of the serially diluted 383 
solutions of the compounds on the cell media were performed. The assays were performed as described 384 
by Givens et al.[41] In brief, MDA-MB231 and MCF7 cells were plated at 5000 and 10000 cells/well, 385 
respectively, in media (100 μL) in tissue culture 96-well plates (Cultek). After 24 h, the media was 386 
replaced by 100 μL/well of serial dilutions of the drugs. Each point concentration was run in triplicate. 387 
Reagent blanks, containing media plus colorimetric reagent without cells were run on each plate. The 388 
blank values were subtracted from the test values and were routinely 5–10% of the uninhibited control 389 
values. The plates were incubated for 72 h. The hexosaminidase activities were measured according to 390 
the following protocol: the media containing the cells were removed, and the cells were washed once 391 
with phosphate-buffered saline (PBS), and substrate solution [60 μL; pnitrophenyl N-acetyl-β-d-392 
glucosamide 7.5 mm (Sigma N-9376), sodium citrate 0.1 m, pH 5.0, 0.25% Triton X-100] was added to 393 
each well and incubated at 37 °C for 1–2 h; after this incubation time, a bright yellow color appeared; 394 
then, the plates were developed by the addition of developer solution [90 μL; Glycine 50 mm, pH 10.4; 395 
ethylenediaminetetraacetic acid (EDTA) 5 mm], and the absorbance was recorded at 410 nm. 396 
 397 
Supporting Information (see footnote on the first page of this article): Characterization data (elemental 398 
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.581 
Legends to figures 582 
 583 
Figure 1. Selected 3,5-disubstituted pyrazoles (I–V) described previously, the new ligand used in this 584 
work (1), and the PdII complex trans-[Pd{κ-N-(1-{MeO(CH2)2}-3,5-Ph2-{C3HN2})}2Cl2] (Va). 585 
 586 
Scheme 1. i) Toluene, benzyltriethylammonium chloride (BTAC), NaOH (40 %), and MeO(CH2)2Cl at 587 
370 K for 24 h. 588 
 589 
Scheme 2. i) Na2[PdCl4] in MeOH (298 K, 1 h) or [PdCl2(dmso)2] in MeOH, reflux, 1 h (molar ratios 590 
1/PdII = 1 or 2, see text and Table 1, Entries 1 and 2); ii) Pd(OAc)2, toluene, reflux, 24 h; iii) SiO2 591 
column chromatography; iv) LiCl (50% excess) in acetone at 298 K (1 h) followed by treatment with 592 
PPh3 (molar ratio 3/PPh3 = 1:1) in CH2Cl2 at 298 K for 1 h; v) cis-[PtCl2(dmso)2] in MeOH, reflux; 593 
vi) cis-[PtCl2(dmso)2] and NaOAc (molar ratio 1/PtII/OAc– = 1:1:2), toluene/methanol (5:1), reflux, 24 594 
h. 595 
 596 
Figure 2. Molecular structure of 2. Hydrogen atoms have been omitted for clarity. Selected bond 597 
lengths [Å] and angles [°]: Pd1–N1 2.007(4), Pd1–Cl1 2.3013(17), C22–O1 1.465(10), N2–C13, 598 
1.354(8), N2–N1 1.364(7), N2–C20 1.460(8), O1–C21 1.390(9), N1–C24 1.336(8), C20–C21 1.495(11), 599 
C13–C12 1.387(9), C13–C14 1.479(9), Fe–C(average value of Fc moiety) 2.037(9), C–C(average for 600 
Fc) 1.41(4), N1–Pd1–Cl1 88.95(14). 601 
 602 
Figure 3 Molecular structure of the dimetallic molecules in the crystal structure of 6·CH2Cl2·MeOH. 603 
Solvation molecules and hydrogen atoms have been omitted for clarity. Selected bond lengths [Å] and 604 
angles [°]: Pt1–N1 2.0127(4), Pt1–S1 2.2037(13), Pt1–Cl1 2.2868(12), Pt1–Cl2 2.3184(13), S1–O1 605 
1.466(4), S1–C30 1.766(6), S1–C31 1.778(6), O2–C28 1.409(6), O2–C29 1.429(6), N1–C13 1.338(6), 606 
N1–N2 1.364(5), N2–C14 1.362(6), N2–C(27) 1.455(6), Fe–C (Fc unit) 2.044(6), C–C (average value 607 
for the Fc moiety) 1.42(1), N1–Pt1–S1 91.89(12), S1–Pt1–Cl1 90.79(5), N1– Pt1–Cl2 87.34(12). 608 
 609 
Figure 4. Comparative plot of the IC50 values [μm] of 1, V, their closely related derivative IV, and 610 
cisplatin against the MCF7 and MDA-MB231 breast cancer cell lines. 611 
 612 
Figure 5 Comparative plot of the IC50 values [μm] of the free ligand 1, the PdII complexes 2–4, and the 613 
trans and cis isomers of [Pt{κ-N-(1-{MeO(CH2)2}-3,5-Ph2-4-{CH2Fc}–{C3N2})}Cl2- (dmso)] (5 and 614 
6, respectively) against the MCF7 and MDAMB231 breast cancer cell lines and the cisplatin-resistant 615 
colon cancer cell line (HCT-116). For comparison, the data obtained for cisplatin under identical 616 
experimental conditions are also included. 617 
618 





































Table 1. Summary of experimental conditions [reagents, molar ratios, solvents, temperature (T) and 656 
reaction time (t)] used to prepare the new PdII complexes 2–4 (Entries 1–4) and PtII compounds 5 and 6 657 




Table 2 Cytotoxic activities (IC50 values in μm) against breast cancer cell lines (MCF7 and MDA-662 
MB231) and the cisplatin-resistant HCT-116 colon cell line for the pyrazoles. To ease the identification 663 




Table 3 Crystal data and details of the refinement of the crystal structures of 2 and 6·CH2Cl2·MeOH. 668 
 669 
 670 
 671 
 672 
